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Summary
Vascular endothelial growth factor (VEGF) is a potent stimulant of angiogenesis. SU5416, is a small molecule tyrosine
kinase inhibitor, and a potent inhibitor of VEGF- mediated Flk-1 receptor signaling. Intravenous agent SU5416 has shown
evidence of biological activity against a variety of tumor types. The current intravenous dosing regimen is not optimal
for long-term administration, which is needed for optimal efficacy. The aim of this study was to evaluate the safety
profile and pharmacokinetics of a Nanocrystal Colloidal DispersionTM (NCD) SU5416 formulation in humans. Patients
with advanced and/or metastatic solid organ tumors were included in the trial; various SU5416 regimens were tested for
tolerability, safety and were evaluated concerning pharmacokinetics. The results of this study indicate that induction of
clearance after oral dosing of NCD SU5416 in humans occurs and is greater than following IV administration. It has been
confirmed that SU5416 is a high clearance compound, also as an oral NCD formulation. The NCD formulation was well
tolerated, but no effective drug serum levels could be achieved. These data help to understand the ADME (Absorption,
Distribution, Metabolism, Excretion) properties of indoline chemical class compounds. The lessons learned should be
applied in the development of next generation indoline anti-angiogenic and anti-tumor compounds.
Introduction
New blood vessels are required for the growth of solid
tumors beyond a volume of 1–2 mm3. Tumors that lack
adequate vasculature undergo hypoxia, and become con-
sequently necrotic or apoptotic [4]. Tumors that undergo
neo-vascularization not only enter a phase of rapid growth
but also demonstrate increased metastatic potential. Im-
munohistochemical studies on tumor sections from mar-
gins of growing tumors show a preponderance of blood
vessels, irrespective of tumor type. This preponderance
of blood vessels is a result of angiogenesis triggered by
factors released from hypoxic tumor cells that migrate to
nearby blood vessels and stimulate growth of endothelial
cells. One of the most potent stimulants of angiogenesis
is vascular endothelial growth factor (VEGF) [2]. Data
concerning the expression of VEGF in colorectal can-
cer demonstrated a correlation of progression of disease
with VEGF expression and it also showed to be an inde-
pendent prognostic factor in colorectal cancer and other
malignancies [3, 4].
Inhibition of neo-vascularization driven by VEGF ap-
pears to be a promising approach to reduce or prevent tu-
mor re-growth or proliferation of metastases in advanced
solid tumors [5, 6]. The search for the receptor whose
selective inhibition will prevent new blood vessel growth
has been the focus of basic research for the last ten years.
Although there are multiple receptors whose expression is
restricted to endothelial cells, it is believed that the Flk-1
receptor plays a role in angiogenesis and thus, its inhibi-
tion may have therapeutic benefit for cancer patients.
SU5416 (Z-3[(2,4-dimethylpyrrol-5-yl)methyldenyl]-
2-indolinone; generic name: semaxanib), is a small
molecule tyrosine kinase inhibitor. In vitro, SU5416
inhibits Flk-1 receptor phosphorylation with an IC50
of approximately 1 mM. It inhibits VEGF-stimulated
proliferation of endothelial cells with IC50 values of ap-
proximately 0.04 mM. The inhibitory effects of SU5416
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are time dependent. This molecule has been primarily
studied as an intravenous agent in patients with a variety
of advanced malignancies and has shown preliminary
evidence of biological activity against a variety of tumor
types as an intravenous agent [7]. However, it seems that
angiogenesis inhibitors require long-term administration
for optimal efficacy. The current intravenous dosing
regimen, twice-weekly infusions, is rather cumbersome
and probably not optimal for long-term administration.
In addition, SU5416 is classified as a high-clearance
compound following IV administration [8].
The aim of this study was to evaluate the safety, tox-
icity, and pharmacokinetics of a Nanocrystal Colloidal
Dispersion (NCD) SU5416 formulation in humans. If the
safety and pharmacokinetic (PK) profile of the single dose
proves to be acceptable, a variety of dosing regimens were
to be explored to determine the impact of repeat dosing
on the pharmacokinetics of oral SU5416.
Patients and methods
Patient selection
Patients were eligible if they were at least 18 years of
age with histologically proven advanced solid tumors.
They could have received one or more prior systemic
chemotherapy regimen, provided that the treatment-
free interval was ≥4 weeks (≥6 weeks in case of
mitomycin-C and nitrosourea) and that it did not con-
tain high-dose chemotherapy. Patients agreed to use ef-
fective contraception, if applicable. All at-risk female
patients were required to have a negative serum preg-
nancy test within 7 days prior to study drug administra-
tion. Patients were required to have a life expectancy
of at least 12 weeks, an Eastern Cooperative Oncol-
ogy Group (ECOG) performance status of ≤2 and ad-
equate hematological reserve (absolute neutrophil count
(ANC) >1,500/mm3; hemoglobin >10 g/ml; platelet
count >100,000/mm3), no significant liver function ab-
normality (bilirubin ≤35 µmol/L, and/or serum transam-
inases, alanine aminotransferase (ALT) and aspartate
aminotransferase (AST) <3.0 upper limit of normal) and
no significant renal function abnormality (serum creati-
nine <160 µmol/L or creatinine clearance <50 mL/min).
Patients with a history of myocardial infarction in the
past 12 months, severe or unstable angina pectoris, and
patients, who underwent coronary or peripheral artery by-
pass surgery within the last two years were excluded. The
latter could be enrolled after consultation with a cardiol-
ogist confirming that the disease was stable.
Written informed consent was obtained from each pa-
tient. The protocol, patient information and informed con-
sent form were approved by the local ethics committee
and notified by the national regulatory authorities.
Treatment and PK-sampling plan
In the first stage of testing, 5 patients received a single
intravenous dose of SU5416 on day 1. On day 8, each
patient received a single dose of oral NCD SU5416. The
IV and the oral doses were 75 mg per administration. The
half-life for the IV-formulation is approximately 55 min-
utes [9]. It was estimated that 3–6 patients were sufficient
per dose-level to assess the bioavailability of the oral for-
mulation. Plasma samples were collected on day 1 and
on day 8 for PK analysis at the following timepoints:
– IV: Before infusion, immediately prior to EOI, 5, 10,
20, 30, 45, 60, 120, 180, 240 following infusion.
– PO: Before ingestion, 30, 45, 60, 90, 120, 180, 240
following ingestion.
The same timepoints were applicable for the second
stage as well.
In the second stage of testing, patients (n = 3 per group;
if greater than 30% variation in bioavailability between
patients was observed, the group size was to be increased
to 6) were to receive an initial intravenous dose of SU5416
on day 1 as a control and oral doses of NCD SU5416 start-
ing on day 8. Based on safety and PK data observed in the
first stage of testing, different repeat-dose regimens were
to be tested, including weekly dosing (Days 8, 15, and
22), twice weekly dosing (Days 8, 11, 15, 18, and 22),
and daily dosing (Days 8 through 21). Dose escalation
(from 75 to 150 to 300 mg daily dose) was to occur for 1
of these regimens based on the most frequent administra-
tion consistent with acceptable safety and PK parameters.
Dose escalation was to discontinue if there were 2 or more
patients in a dose group with unacceptable toxicites being
defined as:
– toxicity grade change in ALT, AST, alkaline phos-
phatase or bilirubin lasting >7 days (possibly or prob-
ably related to drug)
– toxicity grade change in diarrhea (>Grade 1) lasting
more than 7 days with supportive care
– new onset change in parameters of thrombosis (PT or
APTT)
– Serious Adverse Events or Grade 3,4 or fatal Adverse
Event (possibly or probably related to drug).
Patients were to be screened within 14 days prior to study
drug administration and drug levels to be evaluated for
toxicity from the first day to the last day of dosing plus at
a follow-up visit 7 days following their last dose of drug.
Patients with no signs of progressive disease were given
the option, at the discretion of the treating physician, to
receive IV SU5416 as compassionate use treatment.
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The protocol called for the use of dexamethasone and
H1- and H2-blockers as pre-medications for the SU5416
infusion. All 14 patients (100%) used dexamethasone,
H1-antagonist (Clemastine) and H2-antagonist (Raniti-
dine) as premedications. SU5416 was administered via a
venous access device.
For PK the following procedure was applied:
1. 4 ml blood was collected in a vacuum tube containing
heparin; tube was gently inverted 15 times in order
to completely mix blood and heparin; specimen was
placed on ice; tubes had to be kept at 2–8◦C at all
times.
2. Samples was centrifuged: 3500 rpm at 4◦C for 10
minutes
3. Upper layer was transferred with a glass pipette to a
Nalgene cryovial (1.5 ml)
4. Tubes were stored at −70◦C and sent packed in dry ice
to Specialty Laboratory in Santa Monica, California
for analysis.
Bioanalytical methods
SU5416 plasma concentrations were determined using a
validated HPLC assay with UV detection by Specialty
Laboratories. Two oxidative metabolites, an alcohol des-
ignated SU9838 and a carboxylic acid designated SU6595
were determined. Aliquots of plasma samples (200 ∗ L)
were acidified by the addition of 1 M hydrochloric acid
(10 ∗ L). The internal standard SU5614 (5.0 mg/mL,
50 ∗ L) was added and compounds of interest extracted
by the addition of acetonitrile (1.5 mL). The mixture
was centrifuged, the organic layer decanted from the pre-
cipitated proteins and evaporated to dryness under dry
nitrogen. The residues were reconstituted with DMSO:
CH3CN:Mobile Phase, 2:4:3 vol:vol and injected onto a
reverse-phase column. The mobile phase gradient con-
sisted of 10 mM ammonium formate pH = 2.6 and ace-
tonitrile over 30 minutes at a flow rate of 1.2 mL/minute.
The column eluant was monitored with a UV/visible de-
tector set at 440 nm.
The assay is linear from 10 to 2000 ng/mL. Intra-
assay coefficients of variation fall between 2 and 10%
tested at low (100 ng/mL) medium (500 ng/mL) and high
(2000 ng/mL) plasma concentrations. Inter-assay coef-
ficient of variation is between 3 and 6% over the same
range of concentrations; accuracy is 94 to 99%. Quality
control samples at 3 different concentrations were devel-
oped to be included with each analytical run and mon-
itored using Westgard rules in compliance with Good
Laboratory Practice. The lower limit of quantitation for
SU5416, SU6595 and SU9838 were 10, 8 and 18 ng/mL,
respectively.
Pharmacokinetic analysis
SU5416 PK parameters were calculated using non-
compartmental methods using Kinetica (Version 3.1, In-
naPhase, Corp). The primary PK parameters evaluated
for SU5416 were Cmax and AUC. In addition, the sec-
ondary PK parameters were also evaluated: Tmax, CL, Vz,
t1/2, and oral bioavailability. The following pharmacoki-
netic parameters were determined by noncompartmental
methods:
Cmax: Peak plasma concentration was identified by
inspection of individual subject concentration-time
curves.
Tmax: Time of observed peak plasma concentration
was identified by inspection of individual subject
concentration-time curves.
AUC0-tlast: Area under the plasma concentration-time
curve from time zero to the time (T) of the last de-
tectable concentration. AUC0-t(last) was calculated us-
ing the trapezoidal rule.
Vz: Volume of distribution based on the terminal phase
was calculated as Vz = Dose/AUC ∗ lz; where lz rep-
resents the terminal slope
CL: Total body clearance was calculated as CL =
Dose/AUC
t1/2,z: Terminal elimination half-life was calculated as
t1/2,z = 0.693/lz, where the apparent elimination rate
constant, lz, was estimated by least-squares regression
of values in the terminal log-linear region of the plasma
concentration-time curves.
F(oral): Oral Bioavailability;
F(oral) = AUC0-tlast (oral)
∗Dose (IV)/AUC0-tlast (IV) ∗ Dose (oral)
PK-parameters at the different timepoints were com-
pared by calculating%-age of deviation of the values.
Analyses are descriptive in nature.
Results
The 14 patients who received SU5416 treatment com-
prised the intent-to-treat (ITT) population. Of these, five
patients (36%) were treated under Stage 1 (single dose of
75 mg of oral SU5416). Nine patients (64%) were treated
under Stage 2. Of these, three patients (21%) received
weekly dosing of study drug (75 mg of oral SU5416 on
days 8, 15 and 22); three patients (21%) received twice
weekly dosing of study drug (75 mg of oral SU5416 on
days 8, 11, 15, 18, 22); and another three patients (21%)
received daily dosing of study drug (75 mg of SU5416
on days 8 through 21). One patient (7%) discontinued the
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Table 1. Patient baseline and disease characteristics
Male/Female n = 8/n = 6
Median age in years (range) 51 (25–69)
ECOG score 13 pts. With ECOG 1 at baseline
Disease characteristics Solid organ tumors.
Non-small cell lung cancer (n = 4)
Colorectal cancer (n = 2)
Others (n = 8)
Previous therapies Surgery: all patients, n = 14
Radiotherapy: n = 11 (79%)
Systemic therapy: n = 13 (93%)
study due to death. Thirteen patients (93%) completed
the study.
One patient (7%) was enrolled in the study with viola-
tions of inclusion/exclusion criteria. A 69-year-old white
male with a history of metastatic colon carcinoma had re-
ceived surgery, radiotherapy, and systemic therapy. This
patient had hemoglobin value of <10 mg/mL at screen-
ing.
All analyses were performed using the data set that
contained all data for all patients who received at least 1
dose of oral SU5416, the ITT population.
It became apparent that no effective drug serum levels
could be achieved with the NCD-formulation, therefore
the number of patients were not increased as originally
foreseen in the study protocol. For the same reason, no
dose escalation was performed.
Demographic and other baseline characteristics
Baseline characteristics of the 14 recruited patients are
summarised in Table 1.
Patients were polymorbid and most of them had signs
and symptoms caused by the advanced stage of their tu-
mor. Consequently, all patients used concomitant medi-
cation.
Dosage information
All patients received 75 mg IV SU5416 except 1 patient
in the Stage 2, twice-weekly group who received 50 mg
inadevertently. All infusions were to be administered at a
fixed infusion rate of 200 ml/hour, which resulted in in-
fusion times of 30–60 minutes. According to the infusion
records, 5 patients had IV SU5416 infusions interrupted.
In all these patients, infusions were interrupted due to
AEs such as mild or moderate pain at the injection site.
All patients received oral SU5416 and all completed
the schedules. All oral doses were 75 mg.
Table 2. SU5416 Mean (± SD) Pharmacokinetic Parameters follow-
ing IV Infusion of SU5416 (75 mg) and Single Oral Dose of SU5416
(75 mg)
Parameters∗





Cmax (ng/mL) 2810 ± 1110 233 ± 343
Tmax (minutes) NC† 67 ± 26
AUC 0−tlast (ng/mL∗
hour)
1210 ± 383 220 ± 340
Clearance (mL/min) 47.5 ± 23.2 9.23 ± 7.51
Vz (mL) 2900 ± 1430 NC†
Half-life (minutes) 43.5 ± 12.4 NC†
Bioavailability NC† 19 ± 27.4
∗Cmax = peak plasma concentration, AUC0− t (last) = area under plasma
concentration- time curve, Vz = volume distribution base on the terminal
phase.
†NC = Not calculated.
Pharmacokinetics
The peak concentration and the area under the curve of the
oral SU5416 equaled only approximately 10% of the val-
ues achieved following the IV administration of SU5416
(Table 2). The IV pharmacokinetics were very similar to
those observed in previous studies.
Plasma concentrations were generally lower during
Days 15 and 21/22 as compared to, Day 8. By Day 15, a
number of patients’ SU5416 concentrations were below
the level of detection. Mean concentrations (Cmax) of
oral SU5416 were approximately 12-fold lower than those
observed following IV infusions. The mean peak concen-
trations following a single oral dose of NCD SU5416
were observed at 67 minutes. The mean bioavailability
for a single dose and weekly, twice weekly, and daily
dosing of NCD SU5416 on day 8 were 18.9, 20.6, 20.7
and 36.8% respectively. However, there was a large inter-
patient variability. One patient had an oral bioavailability
of 1.3% (Table 3).
The pharmacokinetics of NCD SU5416 following oral
administration exhibited large inter- and intra-patient
variability. With the oral formulation used in this study
only 10–15% of plasma concentrations of SU5416 could
be achieved following a single administration compared
with the IV SU5416. In addition, the oral absorption of
NCD SU5416 was highly variable ranging between 1.3
to 68%. SU5416 concentrations were lower during Days
15 and 21/22 as compared to day 8 suggesting induction
of clearance.
Safety
The oral SU5416 was generally well tolerated, and there
were no apparent differences between groups in likelhood
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Table 3. Mean SU5416 ( ± SD) pharmacokinetic parameters following three different oral dosing schedules
Treatment AUC Day 8 AUC Day 15 AUC Day 21/22 Induction of clearance
Oral
Once weekly (n = 3) 156 ± 117 131 ± 140 141 ± 90 10%
Twice weekly
(n = 3)
329 ± 187 117 ± 92 198 ± 321 40%
Daily dosing (n = 3) 412 ± 111 21 ± 36 9 ± 16 98%
The calculation was made by comparison of the AUC measured on Day 8 with those on day 21/22.
of experiencing SAEs or treatment-related adverse events
(see Table 4).
Discussion
A large inter- and intrapatient PK-variability has been
observed. During metabolization SU5416 is converted
to a number of metabolites, the pattern and levels of
which vary markedly. Hepatic microsomes from hu-
mans form six metabolites. The predominate metabo-
lite was identified as the primary alcohol SU9838, re-
sulting from oxidation of 5-methyl group on the pyrrol
ring SU5416. SU9838 accounts for approximately 41%
of the total metabolites formed by human microsomes
after a 15 minute incubation. Additional SU5416 mi-
crosomal metabolites were identified as further oxida-
tive products of SU9838, e.g. the carboxylic metabolite
SU6595, or products remaining from ring hydroxylation
[10]. The conversion of SU5416 to SU9838 is primar-
ily catalyzed by CYP1A2 with minor contributions from
other enzymes. The formation of SU6595, appears to be
entirely catalyzed by CYP1A2. A correlation analysis be-
tween the CYP1A2 activity and the formation of SU9565,
SU9838, or the sum of the two metabolites showed that
SU9838 behaved as primary metabolite, in that its for-
mation strongly correlated with CYP1A2 activity. These
results suggested that CYP1A2 plays a major role in con-
verting SU5416 to the carboxylic acid without release
of intermediate alcohol metabolite. Thus, the metabolism
of SU5416 by CYP1A2 undergoes “concerted” oxidation
to the alcohol SU9838 and then to the carboxylic acid
SU6595 [11].
In vitro liver microsomal analysis showed that
metabolism of SU5416 increased by a factor 2–3 in ani-
mals receiving multiple IV doses of the drug. The activity
of CYP1A2 increased two-folds in the treated group com-
pared to the vehicle control group. Another study in dogs
treated with SU5416 at 20 mg/kg/day orally for 14 days
detectable plasma levels of SU5416 were seen on Day 1 of
dosing, but on Day 13 of repeated dosing, no SU5416 was
detectable in plasma. Liver tissue analysis showed that re-
peated SU5416 dosing produced an 17-fold increase in
the activities CYP1A2, hepatic SU5416 metabolism was
increased by at least 8-fold [12]. A further in vitro study
Table 4. Summary of most frequent and most severe treatment-emergent adverse events and hematological toxicites with
SU5416 (n = 14)
Adverse event Mild Moderate Severe Life-threatening Fatal
Any ae 5 5 2 1 1
Vomiting 6 0 0 0 0
Nausea 3 1 0 0 0
Dyspepsia 0 0 1 0 0
Asphyxia 0 0 0 0 1
Hematoma 0 0 1 0 0
Back Pain or exacerbated pain 0 1 2 0 0
Injection site pain or burning 4 3 0 0 0
Weakness 1 0 1 0 0
Narcolepsy 0 0 1 0 0
Urinary Incontinence aggravated 0 0 0 1 0
Values reflect number of patients.
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confirmed that SU5416 produced a time and concentra-
tion dependent induction in the CYP1A2 promotor driven
induction of luciferase activity in TV101 cells [13, 14].
Our study showed that induction of clearance after oral
dosing of NCD SU5416 in humans occurs substantially
and is even greater than following IV administration.
However, a phase I study with once-weekly dosing of
SU5416 maintains a comparatively higher systemic ex-
posure for a given dose of that drug, as it prevents the
induction in clearance seen with twice-weekly infusions
and SU5416 [15]. A typical long-lasting inhibitory activ-
ity in vitro and in vivo was suggested for SU5416. It is
preferentially concentrated in cells, and the cells maintain
an inhibitory concentration of SU5416 for a prolonged
period even when the compound is no longer present in
the medium [16]. Less hydrophobic compounds such as
SU6668 do not demonstrate long-lasting activity or con-
centration in similar studies [16].
It has been confirmed in this clinical trial that SU5416
is a high clearance compound, also as an oral NCD for-
mulation. The development of that compound was not
pursued, because it was unlikely that effective plasma
concentrations could be achieved with this formulation,
with SU5416 as such, and the data discussed in this pa-
per help to understand the pharmacokinetic properties of
indoline chemical class compounds. The lessons learned
should be applied in the development of next generation
indoline anit-angiogenic and antitumor compounds.
Repeated dosing of SU5416 markedly induced hepatic
CYP1A activity in vivo, and this induction is most likely
responsible for the attenuation of exposure observed in
various species including humans upon repeated dosing.
There is an increase of certain AEs with SU5416 in-
cluding vomiting, nausea, and injection site pain and
burning. These are known and expected risks in relation to
the administration of SU5416. The results of hematology,
serum chemistry, urinalysis, vital sign measures, ECGs,
physical examinations and toxicity evaluations did not in-
dicate any unexpected risks for SU5416 administration.
The oral NCD formulation of SU5416 was well tolerated
and safe. It has to be taken in consideration, though, that
only 10–15% of plasma concentrations could be achieved
compared with the IV formulation. These levels are not
likely to be therapeutic.
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